Placebo Response

In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response has a negative influence when testing the statistically significant superiority of active compounds compared to placebo.

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative influence when testing the statistically significant superiority of active compounds compared to placebo.

The placebo response exerts a confusing influence when testing the statistically significant superiority of active compounds compared to placebo in analgesia randomized clinical trials (RCTs). Furthermore, the magnitude of this effect has tended to increase over time with the year of trial completion, including in neuropathic pain trials.

In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response tends to increase with the year of trial completion, including in neuropathic pain trials.

This proof-of-concept study on peripheral neuropathic pain patients investigates the potential influence
of the investigator on the placebo response in RCTs while manipulating different variables, including
patient expectation, conditioning and prior experiences, observational and social learning.